Large Cell Neuroendocrine Carcinoma of the Lung Clinical Trials

12 clinical trials for Large Cell Neuroendocrine Carcinoma of the Lung across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors — RECRUITING · PHASE1
• Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors — RECRUITING · PHASE1
• FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum — RECRUITING · PHASE2
• Atezolizumab in Large Cell Neuroendocrine Carcinoma — COMPLETED · PHASE1
• Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC — COMPLETED · PHASE2
• A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung — NOT_YET_RECRUITING · PHASE2
• Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE1
• A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC — NOT_YET_RECRUITING · PHASE2
• DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma — WITHDRAWN · PHASE2
• uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung — OTHER · PHASE2

Refine this search